Oncohema Key

Fig. 5.1 Lepidic pattern adenocarcinoma. Tumour cells line intact, pre-existing alveolar walls. A lesion comprising only this pattern of tumour is adenocarcinoma in situ. This pattern is also common at…

Fig. 17.1 Neuroendocrine cell hyperplasia: Bronchiolar epithelium is undermined by a uniform proliferation of round to oval neuroendocrine cells, without stromal invasion Fig. 17.2 Neuroendocrine cell hyperplasia. Proliferations of cells can be…

Fig. 16.1 A primary lung cancer (left panel) involving the lung of a non-smoker patient treated for recurrent NSCLC with multiple cycles of chemotherapy and radiation. The patient had involvement…

Fig. 9.1 Immunohistochemical staining for ALK is typically diffuse with granular cytoplasmic staining (ALK D5F3, 200×). Image courtesy of Dr. Natasha Rekhtman c-ros Oncogene 1 (ROS1) The prevalence of patients…

Fig. 11.1 Molecular landscape of lung adenocarcinoma. Estimation of mutation prevalence is based on targeted next generation sequencing of lung adenocarcinomas performed at Brigham and Women’s Hospital and Dana–Farber Cancer…

Fig. 8.1 (a) Fusion probe FISH assay negative for translocation (“split signal”). (b) Fusion probe FISH assay positive for translocation (“fusion signal”) Fig. 8.2 (a) Break-apart probe FISH assay negative…

Drug Drug specificity Cut-offs used in trialsa Unless stated, these represent % tumour cells stained: cell membrane staining PD-L1 immunohis​tochemistry primary antibody clone Complementary or companion diagnostic test Staining platform…

Inhibitor Study design Response rate Median PFS (months) Median OS (months) Reference Crizotinib Phase 1 57% Not reached n/a Kwak et al. [5] Crizotinib Phase 1 60.8% 9.7 Not reached…

Fig. 6.1 Tissue processing and tumor characteristics involved in specimen adequacy assessment. Tissue processing fixatives and decalcification methods that are suitable for molecular testing are designated with a green check,…